Is Health Care-Associated Pneumonia (HCAP) Still Relevant?
"Rethinking pneumonia treatment in the age of antibiotic resistance."
Community-acquired pneumonia (CAP) remains a serious infection. However, despite medical advancements, accurately identifying the specific pathogens to effectively prescribe antimicrobial agents remains a challenge. Often, treatment decisions rely on experience and broad assumptions based on common etiologies.
Over the decades, the causes of pneumonia have shifted due to aging populations, increased vulnerability to illness, antibiotic selection pressure, vaccination strategies, and the emergence of new pathogens. Improved molecular diagnostic tests have expanded the array of detectable pathogens, revealing multiple pathogens present in many cases.
Once a clear distinction existed between the pathogens causing CAP and nosocomial pneumonia, but that distinction has blurred. Factors such as repeated hospitalizations in the elderly and those with chronic organ failure, increased numbers of vulnerable hosts in aged-care facilities, and the rise of ambulatory care programs have blurred the lines between hospital and home, impacting pneumonia treatment strategies.
Antibiotic Resistance in Pneumococcus
Antibiotic resistance in Streptococcus pneumoniae, or pneumococcus, is a major concern for clinicians. The source identifies pneumococcus as the main pathogen responsible for community-acquired pneumonia (CAP), as well as meningitis, bacteremia, and otitis media. The provided material does not give a specific prevalence or impact statistic.
Treatment and Detection Challenges
Culture-based approaches to antimicrobial-resistance detection have limitations in sensitivity, turnaround time, and their ability to detect all potential resistance genes. Effective antibiotic selection for pneumonia depends on knowledge of local bacterial pathogens and their susceptibility and resistance profiles. A CAP guideline recommends shorter antibiotic courses—less than five days, with a minimum of three—for outpatients and admitted patients with nonsevere CAP who reach clinical stability. Another guideline warns that broad-spectrum antibiotic therapy selects for resistance and that hospital-exposed patients are at increased risk of pneumonia from resistant pathogens, including MRSA and resistant Gram-negative rods.
Resistance Through the Antibiotic Era
Antimicrobial resistance has affected infectious-disease treatment since the discovery of the first modern antimicrobials. Reports of methicillin-resistant Staphylococcus aureus emerged in 1961, followed by reports of penicillin-resistant S. pneumoniae in 1967. The historical account says the list of resistant organisms has grown over the decades.
The Rise and Fall of HCAP
In 2005, the American Thoracic Society (ATS) and Infectious Diseases Society of America introduced health care-associated pneumonia (HCAP) as a distinct category. This was based on the premise that certain risk factors identified patients at high risk of pathogens not covered by typical CAP empirical therapy. Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa were of particular concern, as they were becoming more common in patients from the community in tertiary centers in the United States.
- Limited Predictive Power: HCAP risk factors often fail to accurately predict the presence of drug-resistant pathogens (DRPs) like Pseudomonas aeruginosa and MRSA outside of specific locations.
- Variable Predictive Power: The predictive power of putative risk factors is highly variable, except for a prior culture of these pathogens.
- Overuse of Antibiotics: Global application of HCAP guidelines has not improved outcomes and has led to overuse of anti-MRSA and antipseudomonal antibiotics.
New Treatments and Vaccine Research
A review of community-acquired pneumonia caused by antibiotic-resistant pathogens reports that new antibiotics have been approved for CAP and are active against multidrug-resistant S. pneumoniae. The CDC says new pneumococcal vaccines will be critical to reducing the remaining burden of antibiotic-resistant S. pneumoniae infections. Other recent material describes antibiotics as the primary treatment approach while identifying multidrug resistance as a challenge, and notes that emerging research is examining new antibiotics, delivery methods, and non-antibiotic treatments.
Empiric Regimens for Nonsevere CAP
For hospitalized patients with nonsevere CAP and no risk factors for resistant organisms, consensus guidelines recommend either a macrolide plus a β-lactam or respiratory fluoroquinolone monotherapy. A multicenter retrospective cohort study examined the comparative effectiveness of first-line and alternative antibiotic regimens in hospitalized patients with nonsevere CAP. A separate systematic review and meta-analysis assessed randomized controlled trials of antibiotic treatments for CAP; the provided source material does not report its comparative results.
A Path Forward: Nuance and Local Data
The data suggests that physicians must understand the local epidemiology of CAP. Relying on published data from other sites may lead to undertreatment or overtreatment for antibiotic-resistant pathogens, each with potential adverse impacts. Molecular screening tests can identify presence, clinicians need to obtain sputum cultures to allow de-escalation if these pathogens are not present and document their local prevalence.
Future Challenges from Resistance
A 2024 article on antibiotic resistance in pneumonia describes dual-resistant bacterial isolates and antimicrobial resistance as clinically significant problems that put health at risk worldwide. It reports that studies since the start of the decade have demonstrated a notable increase in resistance among pathogenic bacteria that cause public infections. The provided material does not specify a rate, location, or forecast for this increase.
Clinicians should de-escalate therapy by discontinuing anti-MRSA and/or antipseudomonal coverage if cultures (or molecular testing) do not confirm these pathogens.
Like asking if wearing a thermal jacket is useful, asking if HCAP is useful depends on the circumstance. While appealing to have a simple rule for all situations, pneumonia is complex and cannot be distilled into a one-size-fits-all approach. Clinical skill and knowledge are still required to achieve the best outcomes.